TY - JOUR
T1 - Do hormone treatments for prostate cancer cause anxiety and depression?
AU - Sharpley, Christopher F.
AU - Christie, David R H
AU - Bitsika, Vicki
PY - 2014
Y1 - 2014
N2 - Background: To investigate the relationship between hormone therapy (HT) and incidence of anxiety and depression among prostate cancer patients (PCa). Methods: 526 PCa patients completed a survey about their cancer status, treatment received, anxiety, and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis. Results: Patients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HT. Conclusion: Current HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects seem to decrease after completion of HT.
AB - Background: To investigate the relationship between hormone therapy (HT) and incidence of anxiety and depression among prostate cancer patients (PCa). Methods: 526 PCa patients completed a survey about their cancer status, treatment received, anxiety, and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis. Results: Patients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HT. Conclusion: Current HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects seem to decrease after completion of HT.
UR - http://www.scopus.com/inward/record.url?scp=84903276700&partnerID=8YFLogxK
U2 - 10.1007/s10147-013-0569-y
DO - 10.1007/s10147-013-0569-y
M3 - Article
C2 - 23728883
AN - SCOPUS:84903276700
SN - 1341-9625
VL - 19
SP - 523
EP - 530
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 3
ER -